NCT04320693

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 19, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 25, 2020

Completed
Last Updated

August 19, 2021

Status Verified

April 1, 2020

First QC Date

March 19, 2020

Last Update Submit

August 12, 2021

Conditions

Metastatic Triple-Negative Breast Carcinoma

Interventions

IMMU-132DRUG

IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles

Also known as: Sacituzumab Govitecan

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Triple Negative Breast Neoplasms

Interventions

sacituzumab govitecan

Condition Hierarchy (Ancestors)

Breast NeoplasmsNeoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 19, 2020

First Posted

March 25, 2020

Last Updated

August 19, 2021

Record last verified: 2020-04